Bristol aims for five new meds by 2012

Bristol-Myers Squibb says it plans to introduce five new drugs, including treatments for cancer, diabetes and heart disease, by 2012, as its top-selling medicine, the blood-thinner Plavix, loses patent protection. Report

Suggested Articles

The eight-year deal will initially cover lupus drug Benlysta and could expand to other GSK specialty-care products in the future.

Amarin had big plans for Vascepa after a big label expansion last year, but it lost a patent fight—and now a generic has won FDA approval.

Intercept Pharmaceuticals, eager to market its potential nonalcoholic steatohepatitis medicine obeticholic acid, will have to keep waiting.